Clinical Scorecard: Analysis of Albuminuria Patterns and Their Association with Subclinical and Clinical Heart Failure, Atrial Fibrillation, and Coronary Heart Disease: Insights from the MESA Study

At a Glance

Key Highlights

• Distinct UACR trajectory groups over 5 and 10 years identify subgroups at elevated risk for HF, AF, and CHD, independent of baseline UACR levels.
• Sustained medium to high or rapid rise in UACR is associated with 1.5- to 3.7-fold increased risk of HF, HF subtypes, AF, and CHD.
• Elevated UACR trajectories correlate with increased NT-proBNP, hs-TnT, and myocardial fibrosis measured by cardiac MRI T1 mapping, linking albuminuria to subclinical cardiac injury.

Guideline-Based Recommendations

Diagnosis

• Use longitudinal monitoring of urine albumin-creatinine ratio (UACR) to identify progressive albuminuria trajectories.
• Consider UACR trajectories even in individuals with normoalbuminuria at baseline for cardiovascular risk stratification.

Management

• Target individuals with sustained or rapidly rising UACR for intensified cardiovascular risk management to prevent HF and related conditions.
• Incorporate cardiac biomarker assessment (NT-proBNP, hs-TnT) and imaging (cardiac MRI T1 mapping) for evaluation of subclinical myocardial injury in high-risk patients.

Monitoring & Follow-up

• Regularly monitor UACR over time rather than relying on single measurements to detect progressive albuminuria.
• Follow cardiac biomarkers and imaging findings to assess progression of myocardial fibrosis and risk of HF.

Risks

• Progressive albuminuria increases risk for heart failure, particularly HF with preserved ejection fraction (HFpEF), atrial fibrillation, and coronary heart disease.
• Risk associations persist independent of baseline UACR and are not fully explained by interim AF or CHD events.

Patient & Prescribing Data

Middle-aged to older adults from a multi-ethnic cohort, including those initially normoalbuminuric

Identification of high-risk UACR trajectories may guide early intervention to prevent progression to clinical HF and cardiovascular events; monitoring cardiac biomarkers and myocardial fibrosis can inform treatment response.

Clinical Best Practices

• Incorporate serial UACR measurements into routine cardiovascular risk assessments to detect progressive albuminuria.
• Recognize that even low-level increases in UACR below clinical thresholds carry significant cardiovascular risk.
• Use combined biomarker and imaging approaches to detect subclinical myocardial injury in patients with rising albuminuria.
• Focus preventive strategies on patients with sustained medium to high or rapidly rising UACR trajectories to reduce HF and cardiovascular event incidence.

References

• Multi-Ethnic Study of Atherosclerosis (MESA) Study
• American Heart Association Heart Failure Statistics